|
|
Monday, 9 April 2018 |
08:30 |
|
Registration and welcoming |
|
|
|
|
|
|
|
|
AMD AND MORE: WHAT THE IMAGING TELL |
09:00 |
|
The normal and the pathologic in imaging (SW and NIR Autofluorescence, Fluorescein Angiography, sd OCT, OCT-A) |
09:45 |
|
Pearls, tips and pitfalls in reading and correlating diagnostic imaging |
10:30 |
|
COFFEE BREAK |
11:00 |
|
Multimodal imaging of dry AMD – diagnosis and progression |
11:30 |
|
Best monitoring with imaging of an AMD at neovascular risk |
12:00 |
|
Differential diagnosis and prognostic characteristics of neovascular forms in AMD |
12:30 |
|
Imaging the management of nAMD |
13:00 |
|
LUNCH |
14:00 |
|
Imaging early and late non-responders in AMD |
14:30 |
|
The imaging aspects of the end of treatment |
15:00 |
|
COFFEE BREAK |
15:30 |
|
Multimodal imaging of dystrophies or macular telangiectasia mimicking AMD |
16:00-16:30 |
|
Diagnosis and monitoring a myopic choroidal neovascularisation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tuesday, 10 April 2018 |
|
|
AMD AND MORE: CLINIC |
08:30 |
|
Dry AMD efficacy of treatment: none, support or really treatment? |
09:15 |
|
Anti-VEGF Treatment regimens for neovascular AMD |
10:00 |
|
Real World Outcomes of Anti-VEGF therapy for neovascular AMD |
10:45 |
|
COFFEE BREAK |
11:15 |
|
Anti-VEGF treatment regimens for myopic choroidal neovascularisation and Long-term outcomes |
12:00 |
|
Cases study of management and monitoring of neovascular AMD |
13:00 |
|
LUNCH |
14:00 |
|
Cases study of management and monitoring of PCV |
14:45 |
|
Cases study of management and monitoring of myopic choroidal neovascularisation |
15:30 |
|
COFFEE BREAK |
16:00 |
|
Cases study of management and monitoring of RAP |
16:45-17:15 |
|
Cases study of management and monitoring of other CNV |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wednesday, 11 April 2018 |
|
|
A TECHNICAL INSIGHT OF INTRAVITREAL TREATMENT |
08:30-12:30 |
|
Industry Satellite Symposia |
12:45 |
|
LUNCH |
|
|
|
|
|
|
|
|
ONCOLOGY COURSE: POSTERIOR SEGMENT TUMORS |
13:45 |
|
Diagnosis and management of retinoblastoma and uveal melanoma |
15:15 |
|
COFFEE BREAK |
15:45 |
|
Vascular tumours, differential diagnosis, and treatment |
16:45-17:15 |
|
Practical cases in ocular oncology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thursday, 12 April 2018 |
|
|
DR AND RVO |
08:30 |
|
Safety of intravitreal treatments |
09:15 |
|
Differences in efficacy among the intravitreal treatments for DME |
09:45 |
|
Regimens of treatment and criteria for dealing with poor responders, optimize the results, and lower the burden of treatment |
10:30 |
|
COFFEE BREAK |
11:00 |
|
Real life data of DME intravitreal treatments and patients management |
11:30 |
|
PDR treatment with anti-VEGF: beyond protocol results what is his clinical application? |
12:00 |
|
Intravitreal steroids and anti-VEGF treatment of ME in RVO |
12:45 |
|
LUNCH |
13:45 |
|
Cases study of management and monitoring of DME |
14:30 |
|
Cases study of management and monitoring of ME in RVO |
15:15 |
|
Cases study of management and monitoring of PDR |
16:00-16:45 |
|
Cases study of management and monitoring of other vascular retinopathies (Von-Hipple, Leber-Coats etc.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Friday, 13 April 2018 |
|
|
MICROPULSE LASER COURSE |
08:30 |
|
Subvisible-threshold retinal laser treatments with micropulse lasers: physical principles and guidelines for settingthe laser parameters |
09:30 |
|
Subvisible-threshold retinal laser treatments with micropulse lasers: evidence from prospective randomized controlled clinical trials in the treatment of DME, RVO-ME, and CSC |
10:00 |
|
COFFEE BREAK |
10:30 |
|
Clinical cases review and study of treatment of various retinovascular disorders |
11:30 |
|
New frontiers in the use of micropulse lasers in the treatment of chronic, progressive and degenerative retinal disorders of disparate etiology and pathogenesis |
12:15-13:00 |
|
Test, certificates and farewell |